Introduction
Over the past few years, genome-wide association (GWA) studies have been successful in localizing and identifying genetic regions that are related to common human diseases [1] . But studies have shown that the amount of genetic variation explained by GWA findings for any given disease is often significantly less than the estimated heritability of the disease [2] . One possible reason for the missing heritability is that GWA studies are underpowered to detect genetic variants that possess small effects. Most common human diseases or traits have complex inheritance patterns with multiple underlying genes with small to moderate effects. Therefore, it requires a relatively large sample size for a GWA study to detect signals with such small effects. In order to boost the statistical power of a GWA study, an important direction Key Words p value weighting · Family-wise error rate · Statistical power · Integrative genomic analysis · SLE Abstract Background/Aims: Genome-wide association (GWA) studies have reported susceptible regions in the human genome for many common diseases and traits; however, these loci only explain a minority of trait heritability. To boost the power of a GWA study, substantial research endeavors have been focused on integrating other available genomic information in the analysis. Advances in high through-put technologies have generated a wealth of genomic data and made combining SNP and gene expression data become feasible. Results: In this paper, we propose a novel procedure to incorporate gene expression information into GWA analysis. This procedure utilizes weights constructed by gene expression measurements to adjust p values from a GWA analysis. Results from simulation analyses indicate that the proposed procedures may achieve substantial power gains, while controlling family-wise type I error rates at the nominal level. To demonstrate the implementation of our proposed approach, we apply the weight adjustment procedure to a GWA study on serum interferon-regulated chemokine levels in systemic of recent research is to integrate available genomic information such as gene expression, SNP, copy number variation, transcription regulation, methylation, and protein abundance together in the analysis [3, 4] . With the advances of high through-put technologies, integrating gene expression with SNP information has drawn much attention in the past decade [5] [6] [7] [8] [9] [10] [11] . A recent study incorporating gene expression information into gene association mapping in mice showed assuring results in identifying functional networks that explain phenotypic alterations [12] .
Genovese et al. [13] introduced the idea of utilizing prior knowledge to weight p values from a GWA study. Li et al. [14] adapted the p value weighting idea and proposed using gene expression information to formally derive weights and to apply the derived weights to adjust the p values from a GWA study. They specified weights as 10 
log
,
where p eQTL is the p value for association between a SNP marker and gene expression (these SNP markers have sometimes been referred to as eQTLs). Li et al. [14] demonstrated a power gain when incorporating information of association between SNP markers and gene expression profiles in their study. However, their approach did not utilize the information of association between gene expression profiles and phenotypic outcome of interest.
In this paper, we propose approaches that utilize both SNP-gene expression as well as gene expression-phenotype associations and which are expected to achieve greater power gains than that of Li et al. [14] in some situations. A study-wise threshold for the weight-adjusted p values can then be used to determine genome-wide significance. In addition to the expected power gain, the weights calculated based on gene expression can provide useful information for prioritizing SNPs for further functional validation experiments.
To assess the performance of our proposed approach, we conducted simulation analyses under various scenarios to evaluate the family-wise type I error rates (FWERs) and statistical power. We also compared the performance of our proposed weighting approaches to that of Li et al. [14] in the simulation analysis.
We apply the proposed approach to a study related to lupus activity in systemic lupus erythematosus (SLE) patients. Through experimental data analysis, our primary focus was to demonstrate the implementation of the proposed weighting adjustment approach. SLE is a chronic, inflammatory, autoimmune disease that can cause damage to organs and tissues throughout the body. The exact cause of SLE is unknown, but a combination of genetic and environmental factors is thought to trigger the disease. More than 45 genetic variants are known to be associated with SLE, and over half of them can be linked to the type I interferon (IFN) pathway [15] . The type I IFNs are a family of antiviral cytokines that are implicated in the pathogenesis of lupus, and IFN-inducible transcripts and proteins are candidate biomarkers for this disease [16] [17] [18] [19] . We previously evaluated a panel of 3 IFN-inducible serum chemokines (IP-10, MCP-1, MIP-3β) as predictors of lupus flare [20] . The identification of genetic variants associated with elevated chemokine levels could improve the treatment of SLE patients and may assist in identifying additional disease susceptibility loci.
The paper is structured as follows: in the next section, we describe the study population and the weighting approach in detail, followed by the simulation analysis. Then, the implementation of the proposed approach in the SLE GWA study is described, ending with a discussion and a final conclusion.
Research Design and Methods

Phenotype and Study Population
In this study, our primary outcome of interest is lupus activity in SLE patients. Three IFNs-regulated serum chemokines, i.e. CXCL10 (IP-10), CCL2 (MCP-1) and CCL19 (MIP-3 β ), were measured using SearchLight (Pierce, Woburn, Mass., USA) chemiluminescence sandwich-based immunoassays. A single, normalized, composite chemokine score on a 100-point scale was calculated using the three chemokine measurements as described in Bauer et al. [20] . The chemokine score could serve as a biomarker for lupus activity and predict future disease flares in the patient cohort [20] .
The data we used was collected from 309 SLE patients with consent from the Hopkins Lupus Cohort [21] enrolled through the Autoimmune Biomarkers Collaborative Network (ABCoN) described in Bauer et al. [20] . All patients were Caucasian, and the majority was female. They received treatments for lupus during the study period including hydroxychloroquine, cyclophosphamide, mycophenolate mofetil, azathioprine, methotrexate, chlorambucil, and oral prednisone.
SNP Genotyping and Gene Expression Profiling
Whole genome genotyping for 555,352 SNP markers was carried out using Illumina 550K SNP array version 1 (HJ550v1; Illumina Inc., San Diego, Calif., USA). Gene expression of 24,849 genes was measured using Illumina Human-6 Expression BeadChip; data files were analyzed with Illumina's GenomeStudio gene expression module to report quantile-normalized, backgroundcorrected gene expression signal levels.
Method
In this study, we propose using weights [13, 22, 23] computed and based on gene expression measurements to adjust the p values from GWA analysis. Roeder et al. [24] suggested using weight w i >0 to adjust p value p i and reject null hypothesis H i if the adjusted p value is smaller than the Bonferroni-corrected threshold α / m , where α is the significance level and m is the total number of hypotheses. Hence, the set of rejected hypotheses ( H i ) is defined as:
:
.
Roeder and Wasserman [25] provided theoretical proof that the rejection set R described above controls the FWER at level α , as long as w i > 0 and  w i = 1. Based on their theoretical results, we utilize the p value weighting approach to gain power in detecting signal, while controlling the FWER at the nominal level. After weight adjustment, SNP loci that strongly contribute to a phenotype-associated gene expression will have smaller p values. The weighting mechanism is as follows: we assign a weight w i * to each SNP marker i , such that w i * >0 and the average of all weights  w * is 1. The weight for a given SNP ( L i ) is a product of two parts: w L i E j and w E j P . w L i E j indicates the effect of SNP locus L i on the j -th gene expression measurement E j . The second term w E j P describes whether gene expression measurement E j is associated with the phenotypic outcome P .
To ensure a correct control of the FWER, we use the model below to calculate w L i E j :
from the above regression model is equivalent to β r in the following model:
where r 1 and r 2 are residuals from the following 2 models, respectively:
In equation 1, the reason for adjusting for P is to remove the effect of P , in order to prevent the correlation between weight w L i E j and the GWA p value. In an extreme situation, for example, consider SNP marker L i is not associated with E j , while E j and P are highly correlated. The p value for β L i E j in the model
will be highly correlated with the GWA p value for β in the GWA model
due to the high correlation between E j and P . Hence, after adjusting for the effect of P in equation 1, the p value for β L i E j will be less likely to be significant, yielding a derived weight not highly correlated with the GWA p value.
Similarly, we adjust for L i when calculating weight w E j P using the model
Then, the product of the 2 weights is used to describe the effect of SNP locus L i on P through E j . The useful benefit of taking the product of 2 weights is that if either w L i E j or w E j P is zero, then the resulting product will be zero. On the other hand, if both w L i E j and w E j P are reasonably large, then taking the product of the two parts will result in an amplified overall weight. A crude weight for SNP locus L i is determined by the maximum of the products among all gene expression measurements:
Finally, we divide crude weights w MP by their average w  MP , so that  w * is 1, as required by Roeder and Wasserman [25] :
With w * MP i , the adjusted p value for the i -th SNP can then be calculated as: p value of SNP reported from GWAS adjusted p value for SNP .
In the weighting approach described above, we assume that the effect of the SNP genotype on the gene expression is linear. More generally, we may code 2 dummy variables to indicate L i = 1 versus 0, and L i = 2 versus 0, respectively, then the χ 2 statistic derived from the likelihood ratio test can be used in replacement of the squared t statistic. Furthermore, in the case-control study design, a similar approach can be applied by deriving the weights through logistic regression.
Because the weights are constructed as the products of 2 parts, to ensure both the associations between L i and E j and also between E j and P are substantial, we propose a trimming method for w L i E j and w E j P as follows: we set
In the analysis below, we set 1 2 1 005 . c c .
Then w * MP i can be calculated as described above. When only a subset of individuals have gene expression profiles available in a dataset, the p values can be derived from the full dataset, and weights can be calculated from the partial dataset. Then, the same weight-adjusting procedure can be implemented as described above. The R source code for implementing the proposed weighting procedure is available at: http://www.biostat.umn. edu/ ∼ yho/research.html.
Simulation
To mimic data from a GWA study, we constructed simulated data using the marginal distribution parameters of the genotype scores of the SNP markers, the gene expression measurements and Using Gene Expression to Improve the Power of GWA Hum Hered 2014;78:94-103 DOI: 10.1159/000362837 97 the phenotype obtained from the SLE study described in the previous section. We selected one SNP marker to be the true underlying SNP ( SNP true ) and simulated a single gene expression level according to this model:
In the described model, β 0 E and σ E 2 were obtained from the mean and the variance of a randomly selected gene expression. The value of the phenotypic outcome was simulated based on the model:
β 0 P and σ P were determined by the mean and variance of the chemokine score in the SLE dataset. We used standardized E 1 in the above equation for the ease of interpreting β P .
To investigate family-wise error control, we randomly selected another 9 non-phenotype-associated SNP markers and 1,000 gene expression measurements from the experimental data in the SLE study. Hence, the simulated dataset consisted of 10 SNP markers, 1,001 gene expression measurements, and 1 continuous phenotypic outcome.
Scenario 1
In the first simulation, we assumed β E = β P = 0 to examine the type I error rate. The results are presented in table 1 . In table 1 , we recorded the fraction of times that a SNP was declared significant at α = 0.05/10 for 4 approaches: the conventional GWA analysis, the weight-adjusted approach with W T MP and without W MP trimming, and Li et al.'s approach [14] . The overall FWERs from the 10,000 simulations were estimated by counting the percent of times when any significant results were reported. In table 1 , we observed the estimated FWERs were close to 0.05 for all 4 approaches. In addition, we observed similar results when assuming β E = 10, and β P = 0. 
Scenario 2
A second simulation was conducted, assuming β E = 0 and β
Scenario 3
In this simulation scenario, the underlying SNP marker L was not associated with outcome P and gene expression E . However, 2 unobserved latent variables (F1 and F2) were in association with the observed L , E and P , as illustrated in figure 1 . This latent model can account population stratification or admixture. In this simulation scenario, we were interested in examining whether the latent variables could create a spurious dependency for the proposed analyses. According to the result shown in table 1 , the FWER remained controlled at the 0.05 level for all 4 approaches in this scenario.
Scenario 4
To assess the power of the proposed weighting approaches, we conducted simulations assuming
The results are shown in [14] suffered a dramatic power loss compared to the GWA approach in this scenario. Their weighting approach only accounted for the association between SNP and gene expression, which resulted in incorrectly assigning higher weights to SNP add .
Scenario 6
In this scenario, we assumed 0 5;
only a subset of all individuals had expression measurements available, but more samples had SNP genotype and phenotype information. In this simulation, we assumed that only 1/3 of all individuals had expression profiles available. The proposed weighting approach still demonstrated a considerable power gain (with an increase in power from 41.9% to 60.1%) compared to the conventional GWA analysis; however, the power gain was less prominent than that of Scenario 4, when the expression profiles for the whole study population were available.
Scenario 7
This scenario assumes a reactive model [26] as illustrated by the diagram below. We assumed a SNP marker L had an effect on outcome P , and the alteration of gene expression E was the result of a change in outcome P . We assumed 's approach) assigned lower weights for SNP markers with gene expression in a reactive model compared to the original GWA p value. In the proposed weighting approaches, the model constructed for calculating w LE (equ. 1) adjusted for outcome P . As a result, w LE was less likely to be large and more likely be reduced to 0 in the trimming approach. Hence, we observed that W T MP assigned the lowest weights for the reactive model.
Scenario 8
This scenario is a modification from Scenario 5, where an independence model was assumed as illustrated in the diagram below. A SNP marker L 1 had an effect on outcome P and also on gene expression E 1 . But P and E 1 were independent. We assumed [14] undesirably assigned larger weights for SNP markers that were in the independent model.
In summary, the proposed weighting procedures control the FWER at the nominal level when L is not associated with E , E is not associated with P , or both. Our proposed methods aimed to find genes that undergo a L → E → P mechanism, where gene expression is in the middle of the pathway. Hence, our methods exhibited the largest power gain in identifying genes described in Scenario 4.
Data Analysis Results
Results
In the SLE dataset described in Section 2, the obtained chemokine score is considered a biomarker for lupus activity for SLE patients. To demonstrate the implementation of the proposed approach, we applied the chemokine score as the primary outcome and performed weight adjustment analyses for SNP loci with an allele frequency >0.1. The simulation results suggested that the trimming approach could allocate more weights on relevant SNP loci. Therefore, we applied W T MP with trimming in the following analysis. [14] . One possible explanation is that these SNP markers might undergo the independent model. The top SNP hit (rs17415112) is located within the EXOSC1 gene. EXOSC1 encodes a core component of the exosome and may be involved in Ig class switch recombination and degradation of mRNA transcripts for histone proteins, which are implicated in SLE [27] . Our results suggest a possible interaction of EXOSC1 and LOC441019, a locus related to immune system, cytokine, and IFN-γ signaling. In addition, several transcripts reported in table 3 are involved in the immune response, inflammation, and cytokine pathways that are known to be associated with active SLE [28] . These include inflammatory caspase-related CARD17 [29] , IFN-inducible IFI35, apoptosis-inducing ligand TNFSF10 [30] , and galectin LGALS9 [31] . Furthermore, according to table 3 , we noticed that there were several SNP markers at the top of the list having lowered p values after weight adjustment. Using the threshold of 10 − 5 , 3 additional SNPs (rs596346, rs624676, and rs514604) became significant. These 3 SNP markers are in linkage disequilibrium and mapped to a noncoding mRNA transcript BC041900. This region is about 500-kb upstream of gene clusters on chromosome 11, where FAM181B , PRCP , SNORA70E , C11orf82 , LOC100506233 , AK311356 , ANKRD42 , and RAB30 locate.
To investigate SNP loci with moderate p values but large weights, we ranked SNP loci with unadjusted p value <10 − 3 and w * MP >1. The top 40 ranked loci are listed in table 4 . The complete list of SNP loci with unadjusted p value <10 − 3 and w * MP >1 is available in online supplementary table S1 (www.karger.com/doi/10.1159/000362837). Interestingly, in some cases, multiple SNPs on different chromosomes appear to interact with a single transcript. Among these transcripts are BST2, PARP12, SP140, TIMM10, UBQLNL, and XAF1. This suggests that distinct genetic variants may lead to an altered expression of a single gene and provide divergent ways to trigger elevated chemokine levels. In table 4 , there are 11 SNP markers which were upweighted ( w * MP >1) using our approach but downweighted by Li et al.'s approach [14] . These differences in weights could be due to the mechanism described in Scenario 2.
Functional Annotation
Many of the transcripts identified in our study are known to be regulated by type I IFN [16] . Furthermore, several of the transcript abundances are also known to be altered in blood cells of patients with SLE compared to healthy controls [16] . Among those transcript abundances that are both altered in SLE and IFN inducible are IFI35, TNFSF10, XAF1, PARP12, BST2, ISG15, DDX58, HERC6, and MT2A. Only a few transcripts in our results (SP140, PSME2, and LGALS9) are IFN inducible but were not observed to be changed in our studies of SLE patients.
While the current findings require validation to confirm the association of these variants with gene expression and serum chemokine levels, several of the identified loci harbor genes with known functions related to the immune system. These include DKK3, which plays a role in peripheral CD8 T-cell tolerance [32] ; transcription factor NR1D1, which regulates the production of inflammatory cytokines [33] ; RGS9, which may have a role in chemokine-induced lymphocyte migration [34] , and SDK1, which is associated with combined variable immunodeficiency [35] . In addition, several expressed genes listed in the ninth column of table 4 , which interact with the SNP variants described above, participate in cellular apoptosis, such as XAF1, UBQLNL, TIMM10, BST2, HERC6, ISG15, and PSME2 [36, 37] .
Discussion
Through experimental data analysis, our primary focus was to demonstrate the implementation of the proposed weight adjustment approach. In the analysis of SLE GWA data, we identified 3 SNP loci with large weights that became significant after weight adjustment, as shown in table 3 . Several genes listed in tables 3 and 4 have pivotal roles in immune functions. Our results identified several genetic interactions among immune responses and cellular apoptosis pathways and seem to suggest the importance of their interactions in active SLE symptoms. These SNP loci and the corresponding, associated gene expressions provided valuable information for further functional evaluations. A replication of these findings in other cohorts is necessary to demonstrate the biological significance of the additional loci identified by our method.
Yet, we also observed SNP loci with small p values that showed no evidence of gene expression association when analyzing SLE GWA data. This could be so because phenotype contribution mechanisms were not measured in the current study, such as through unmeasured gene expression transcripts, DNA structures, or other mechanisms. These SNPs will not be favored in the proposed weighting method, since they will be downweighted due to a lack of evidence of association with gene expression. These unmeasured mechanisms might explain the moderate differences in p values we observed in the SLE data analysis results described in Data Analysis Results. Hence in practice, we suggest to pursue both (1) SNPs with tiny GWA p values without weighting and (2) SNPs with small weight-adjusted p values. The proposed weighting approach assists researchers to prioritize GWA SNP findings by integrating available genomic information.
In this paper, we demonstrated our method in a paired gene expression and GWA study data from the same cohort. To date, relatively few published studies have utilized gene expression data from the same patients studied by GWA study [38] [39] [40] [41] [42] . However, as appreciation grows for the power of eQTL analysis, efforts such as the Genotype-Tissue Expression project will come to fruition [43] and methods such as ours will facilitate the analysis of such datasets. Therefore, we believe the collection of RNA from GWA study participants for expression profiling will be useful. In addition, if eQTL (SNP, gene expression) data, and gene expression-phenotype data are available from two different sets of cohorts, instead of paired gene expression and GWA study data from the same cohort, our proposed approaches can be easily modified and applied. Our proposal provides a formalized procedure to incorporate additional genomic information into GWA analyses. In additional to gene expression measurements as demonstrated in this paper, with the advent of a wealth of genetic data generated through high-throughput technologies, the proposed method is extendable to integrate other sources of information such as DNA methylation status, transcription regulation, and protein abundance.
The weighted hypothesis testing concept was first introduced by Holm [22] and, since then, theoretical developments have been advanced to form the basis for p value weighting in order to increase power while controlling FWER in a multiple hypothesis testing setting. Roeder and Wasserman [25] provided an applicable theory for constructing weights which control FWER at the nominal level. Roeder et al. [24] applied p value weighting procedures to GWA analysis and demonstrated power gain compared to conventional analysis.
In the spirit of integrating genomic information from multiple sources for power gain, we proposed novel weighting procedures based on the theory by Roeder and Wasserman [25] to incorporate gene expression into GWA analyses. Our simulation results confirmed that the proposed weighting procedure dramatically improved the statistical power of GWA studies, while controlling FWER at the nominal level, when gene expression is in the middle of the etiological pathway. Using this mechanism, our methods demonstrated greater power gain compared to that of Li et al. [14] . It also provides ways to draw valuable information from massive data to assist functional interpretations of GWA signals.
